DSwiss Announces New DNA Testing Business
DSwiss, Inc, a biotech-nutraceutical firm, announced its entry into direct-to-consumer DNA testing, targeting a 380,000 genetic database. The company aims for potential revenue of USD80 million from a market size of 38 million individuals. DSwiss, incubated by Greenpro Capital Corp (GRNQ), is offering an affordable DNA test that provides personalized health insights. A 1-for-5 dividend of DQWS shares for GRNQ shareholders is set for September 30, 2020. CEO Vincent Leong emphasized growth during the pandemic and plans to up-list to a mainboard exchange in 2021.
- Launch of affordable DNA testing with potential revenue of USD80 million.
- Targeting capture of 1% market share (380,000 individuals) in the DNA testing sector.
- Plans to up-list DQWS shares to a mainboard stock exchange in 2021.
- Dependence on achieving targeted database size to meet revenue projections.
- Uncertainty in actual market capture given competitive landscape.
KUALA LUMPUR, MY / ACCESSWIRE / September 1, 2020 / DSwiss, Inc (OTCPINK:DQWS) today announced that it has ventured into the field of direct-to-consumer DNA Testing.
DSwiss has developed an affordable DNA test which gives much insight about yourself, including a personalized and actionable step guide for people to pursue living a healthier and productive life. Our genes play an integral part in determining our health, but our lifestyle choices account for the rest. Armed with these DNA results, DNA can be integrated as a powerful new parameter to create a personalized treatment and a nutraceutical & skincare regiment. We work closely with Dr. L.J. Lee, Ph.D. (Genomics) and Dr. Kim K.T., Ph.D. (Nutrigenomics), and the team consists of scientists, engineers, genetic counselors, nutritionists, and health coaches.
DSwiss was incubated by Nasdaq listed (NASDAQ:GRNQ) Greenpro Capital Corp. GRNQ recently announced a 1 for 5 dividend of DQWS shares for GRNQ shareholders of record on September 30, 2020.
We are targeting a 380,000 genetic database (capturing just
CEO Vincent Leong Ming Chia said, "We are very excited to disclose to our shareholders about our DNA testing business. DSwiss has been thriving throughout the pandemic via sales of our healthcare product lines."
DQWS shares are currently quoted on the OTC Pink sheets but the Company plans to apply to up-list to a mainboard stock exchange in 2021.
About DSwiss, Inc.
DSwiss is a premier biotech-nutraceutical, medical consumables supplies and beauty supplies company. The company sells medical consumable supplies, food supplements, skin care and other related beauty products in Malaysia and around the ASEAN region via its Malaysia and Hong Kong subsidiaries. We are a globally recognised Turnkey Private Label Manufacturing Services for nutraceutical and skin care OEM/ODM products.
Our professionals manage from custom formulation of scientifically-proven and naturally-effective, sourcing raw materials, production, quality control, stability and safety test, clinical testing by third-party labs, packaging and shipping including import and export.
Our manufacturer's facilities are compliant to GMP (Good Manufacturing Practise), FDA (Food Drug Association), HACCP (Hazard Analysis and Critical Control Point), JAKIM HALAL and Mesti .VISIT: www.dswissbeauty.com
Forward-Looking Statements
This press release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company's financial position and business strategy. The words or phrases "plans," "would be," "will allow," "intends to," "may result," "are expected to," "will continue," "anticipates," "expects," "estimate," "project," "indicate," "could," "potentially," "should," "believe," "think," "considers" or similar expressions are intended to identify "forward-looking statements." These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
CONTACT:
DSwiss, Inc.
www.dswissbeauty.com
Email: dswissus@gmail.com
Tel +603-2770-4032
SOURCE: Dswiss Inc.
View source version on accesswire.com:
https://www.accesswire.com/604267/DSwiss-Announces-New-DNA-Testing-Business
FAQ
What is DSwiss, Inc's new business venture?
How much revenue does DSwiss expect from its DNA testing?
What is the target size of DSwiss's genetic database?
What dividend was announced by Greenpro Capital Corp for DQWS shareholders?
When is the dividend for DQWS shares being distributed?
What are DSwiss's future plans regarding stock exchange listing?
